The letter, sent to Congressional leaders in April 2026, calls for mandatory federal requirements for screening synthetic DNA sequences before production. This is not an abstract request about "biosecurity" or "ethical use." It is incredibly specific: they demand that any company synthesizing DNA screen each order against databases of dangerous pathogens. Notably, they want this to become law, not just a voluntary recommendation.
The Problem Nobody Wants to Acknowledge (But Exists)
DNA synthesis has democratized access to biotechnology. Just a decade ago, creating custom genetic sequences required university labs and considerable research budgets. By 2026, you can order synthetic DNA online with the same ease as purchasing chemical reagents for your biotech startup. You simply pay, submit the sequence, and receive the material at your door.
The global gene synthesis market reached $4.2 billion in 2025 and is growing at a solid 18% annually. Companies like Twist Bioscience, Integrated DNA Technologies (IDT), and Synthetic Genomics process millions of orders each year. Most of these are legitimate: academic research, therapy development, agriculture, and biomanufacturing.
But here’s the issue: those same platforms could, in theory, be used to synthesize genetic sequences of dangerous pathogens. Isn’t it alarming to think about the potential consequences of that? Honestly, the speed at which this technology is advancing raises critical questions about regulation and safety.